Friday, July 10, 2026

pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN

Regeneron UK

Regeneron UK is a pharma organization headquartered in Tarrytown, USA. It trades on NYSE under ticker REGN. Primary therapeutic focus areas include Diabetic Macular Edema, Hypercholesterolemia, Asthma, Macular Degenerati

Tarrytown, USA HQ
16,715 Employees
Public company Type
REGN · NYSE Ticker
Company details
Clinical program

Cemiplimab

Phase 2 · small molecule · Metastatic Solid Tumor

Cemiplimab for Metastatic Solid Tumor is a Phase 2 program (small_molecule) at Regeneron UK Limited with 1 ClinicalTrials.gov record(s).

← All Regeneron UK Limited projects Phase 2 small molecule active

Internal code 202000570

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Regeneron UK Limited
Phase
Phase 2
Modality
small_molecule
Indication
Metastatic Solid Tumor
Status
active
Trials
1